Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$4.78 -2.0%	$5.47	$3.18 ▼ $13.53	$225.72M	N/A	353,851 shs	3.17 million shs
COLL Collegium Pharmaceutical	$29.47 -1.6%	$28.15	$23.23 ▼ $42.29	$946.93M	0.63	428,222 shs	167,456 shs
MLYS Mineralys Therapeutics	$16.66 +3.5%	$14.39	$8.24 ▼ $18.38	$1.09B	-0.3	480,548 shs	708,003 shs
PAHC Phibro Animal Health	$23.25 -3.5%	$20.19	$16.16 ▼ $26.55	$942.42M	0.62	198,258 shs	164,187 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-17.98%	+9.42%	-2.40%	-4.31%	+487,999,900.00%
COLL Collegium Pharmaceutical	+0.44%	+0.54%	+10.92%	+0.17%	-12.27%
MLYS Mineralys Therapeutics	+5.09%	+5.99%	+20.60%	+72.75%	+25.68%
PAHC Phibro Animal Health	-0.17%	-2.07%	+39.33%	-0.33%	+32.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALMS Alumis	2.2013 of 5 stars	3.6	0.0	0.0	0.0	2.3	1.7	0.6
COLL Collegium Pharmaceutical	4.0712 of 5 stars	3.4	0.0	0.0	3.0	4.1	0.8	2.5
MLYS Mineralys Therapeutics	2.7745 of 5 stars	3.5	1.0	0.0	0.0	3.2	5.0	0.0
PAHC Phibro Animal Health	3.5371 of 5 stars	0.8	3.0	2.5	1.1	3.1	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	3.22	Buy	$24.86	420.02% Upside
COLL Collegium Pharmaceutical	2.80	Moderate Buy	$43.80	48.63% Upside
MLYS Mineralys Therapeutics	3.00	Buy	$38.00	128.09% Upside
PAHC Phibro Animal Health	1.50	Reduce	$20.00	-13.98% Downside

Current Analyst Ratings Breakdown

Latest ALMS, MLYS, PAHC, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $25.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
4/30/2025	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/2/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00 ➝ $42.00
3/26/2025	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	N/A	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	$664.28M	1.43	$10.68 per share	2.76	$5.99 per share	4.92
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
PAHC Phibro Animal Health	$1.19B	0.79	$2.14 per share	10.87	$6.09 per share	3.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/18/2025 (Estimated)
COLL Collegium Pharmaceutical	$48.15M	$1.22	12.70	4.90	N/A	14.78%	104.67%	18.38%	N/A
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-67.97%	-62.40%	N/A
PAHC Phibro Animal Health	$2.42M	$0.78	48.44	11.07	0.45	1.75%	25.35%	6.21%	N/A

Latest ALMS, MLYS, PAHC, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/18/2025	N/A	ALMS Alumis	-$1.47	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ALMS Alumis	-$1.47	-$1.82	-$0.35	-$1.82	N/A	N/A
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
2/27/2025	Q4 2024	COLL Collegium Pharmaceutical	$1.54	$1.63	+$0.09	$0.36	$179.68 million	$181.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.06%	N/A	61.54%	N/A

Latest ALMS, MLYS, PAHC, and COLL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	11.26	11.26
COLL Collegium Pharmaceutical	3.43	0.97	0.88
MLYS Mineralys Therapeutics	N/A	14.02	14.02
PAHC Phibro Animal Health	2.99	3.20	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
COLL Collegium Pharmaceutical	N/A
MLYS Mineralys Therapeutics	84.46%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	N/A
COLL Collegium Pharmaceutical	2.51%
MLYS Mineralys Therapeutics	25.56%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	N/A	47.22 million	N/A	N/A
COLL Collegium Pharmaceutical	210	32.13 million	30.97 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	33.27 million	Optionable
PAHC Phibro Animal Health	1,860	40.53 million	20.22 million	Optionable

ALMS, MLYS, PAHC, and COLL Headlines

Recent News About These Companies

What Makes Phibro Animal Health (PAHC) a Strong Momentum Stock: Buy Now?

May 21 at 1:06 PM | zacks.com

Phibro Animal Health Co. (NASDAQ:PAHC) Shares Bought by Virtus Investment Advisers Inc.

May 21 at 7:31 AM | marketbeat.com

Graham Capital Management L.P. Buys Shares of 11,650 Phibro Animal Health Co. (NASDAQ:PAHC)

May 21 at 4:12 AM | marketbeat.com

Parkwood LLC Sells 72,723 Shares of Phibro Animal Health Co. (NASDAQ:PAHC)

May 16, 2025 | marketbeat.com

Solid Earnings Reflect Phibro Animal Health's (NASDAQ:PAHC) Strength As A Business

May 16, 2025 | uk.finance.yahoo.com

Phibro Animal Health Co. (NASDAQ:PAHC) Stock Holdings Lifted by Jacobs Levy Equity Management Inc.

May 16, 2025 | marketbeat.com

Cubist Systematic Strategies LLC Makes New Investment in Phibro Animal Health Co. (NASDAQ:PAHC)

May 16, 2025 | marketbeat.com

Centiva Capital LP Takes Position in Phibro Animal Health Co. (NASDAQ:PAHC)

May 15, 2025 | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Q3 2025 Earnings Call Transcript

May 13, 2025 | msn.com

Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term

May 13, 2025 | zacks.com

International Markets and Phibro (PAHC): A Deep Dive for Investors

May 13, 2025 | zacks.com

Bridgeway Capital Management LLC Makes New Investment in Phibro Animal Health Co. (NASDAQ:PAHC)

May 13, 2025 | marketbeat.com

3 Reasons Growth Investors Will Love Phibro (PAHC)

May 12, 2025 | zacks.com

PAHC or BSX: Which Is the Better Value Stock Right Now?

May 12, 2025 | zacks.com

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

May 12, 2025 | zacks.com

Phibro Animal Health Co. (NASDAQ:PAHC) Shares Bought by Algert Global LLC

May 11, 2025 | marketbeat.com

Phibro Animal Health Co. (NASDAQ:PAHC) Stake Trimmed by Dimensional Fund Advisors LP

May 11, 2025 | marketbeat.com

Phibro Animal Health (NASDAQ:PAHC) Shares Gap Down - Should You Sell?

May 11, 2025 | americanbankingnews.com

Phibro Animal Health Corporation (PAHC) Q3 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Phibro Animal Health Co. (NASDAQ:PAHC) Shares Acquired by AQR Capital Management LLC

May 10, 2025 | marketbeat.com

Phibro Animal Health Corp (PAHC) Q3 2025 Earnings Call Highlights: Robust Sales Growth and ...

May 9, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS, MLYS, PAHC, and COLL Company Descriptions

Alumis NASDAQ:ALMS

$4.78 -0.10 (-2.05%)

Closing price 04:00 PM Eastern

Extended Trading

$4.70 -0.08 (-1.65%)

As of 07:21 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Collegium Pharmaceutical NASDAQ:COLL

$29.47 -0.49 (-1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$29.46 0.00 (-0.02%)

As of 05:07 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Mineralys Therapeutics NASDAQ:MLYS

$16.66 +0.56 (+3.48%)

Closing price 04:00 PM Eastern

Extended Trading

$16.75 +0.09 (+0.54%)

As of 07:59 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Phibro Animal Health NASDAQ:PAHC

$23.25 -0.84 (-3.49%)

Closing price 04:00 PM Eastern

Extended Trading

$23.24 -0.01 (-0.04%)

As of 05:07 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time